Jacques Banchereau, PhD Appointed as Chief Scientific Officer at Javelin Biotech

WOBURN, Mass.--(BUSINESS WIRE)-- Javelin Biotech, Inc., a leading technology company specializing in human tissue chip platforms for biopharma research, is delighted to announce the appointment of Jacques Banchereau, PhD as its Chief Scientific Officer (CSO). Banchereau is an internationally recognized immunologist and molecular biologist, renowned for his groundbreaking contributions to the field of immunology and drug discovery.

Over his distinguished 35-year career, Dr. Banchereau has shown exceptional leadership in both academic and industrial research. Having held esteemed roles such as Professor and Director of Immunological Sciences at the Jackson Laboratory for Genomic Medicine, Chief Scientific Officer at Hoffman-La Roche, CSO at Immunai, and Adjunct Professor of Immunobiology at Yale School of Medicine, he has consistently demonstrated his expertise in driving forward scientific inquiry and pharmaceutical innovation.

In his role at Javelin Biotech, Banchereau will oversee the company's scientific strategy, leveraging his vast experience and expertise to drive the development of cutting-edge technology for the modeling of human diseases. His appointment underscores Javelin Biotech's commitment to innovation and scientific excellence in the field of biotechnology.

"We are thrilled to welcome Jacques to the Javelin Biotech team," said Murat Cirit, PhD, CEO of Javelin Biotech. "His outstanding achievements and leadership in immunology and drug discovery make him a valuable addition to our company. We are confident that his expertise will play a pivotal role in advancing our research efforts and driving our mission to support the development of novel treatments for organ-specific diseases."

Banchereau expressed his excitement about joining Javelin Biotech, stating, "I am honored to be part of a company that is dedicated to pushing the boundaries of scientific research. Javelin Biotech's innovative technology has the potential to revolutionize the way we understand and treat complex diseases, and I look forward to contributing to its success."

About Javelin Biotech:

Javelin Biotech is a biotechnology company focused on humanizing preclinical drug discovery with a predictive platform that merges human tissue chips with digital twin technology to develop better medicines faster. The Javelin platform enables the creation of accurate and physiologically relevant models of human tissues, providing valuable insights into disease mechanisms and drug responses, allowing biopharmaceutical companies to reduce their reliance on animal studies and develop better drugs faster.

For more information, visit www.javelinbiotech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240417237133/en/

Kevin O’Handley
[email protected]
(781) 995-3099

Source: Javelin Biotech, Inc.

You May Also Be Interested In

• Korn Ferry Completes Acquisition of AMS
• LNG Energy Group Corp. Extends the Binding Exclusivity Agreement and Letter of Intent to Establish a US$200 Million Strategic JV to Fund Oil and Gas Investments in Venezuela
• Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer